103P Rate of BRCA1/2 pathogenic variants according to family and personal history of cancer in a large cohort of triple-negative breast cancer (TNBC) patients (pts) younger than 60 years of age
Stefania Zovato(Istituto Oncologico Veneto), Valentina Guarneri(Istituto Oncologico Veneto), Federica Miglietta(University of Padua), Sandro Tognazzo(Istituto Oncologico Veneto), Lidia Moserle(Institut d'Investigació Biomédica de Bellvitge), PierFranco Conte(University of Padua), Marco Montagna(Azienda Ospedale - Università Padova), Laura Matricardi(Istituto Oncologico Veneto), Maria Vittoria Dieci(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Elisa Alducci(Istituto Oncologico Veneto), Simona Agata(Istituto Oncologico Veneto), Gino Crivellari(Istituto Oncologico Veneto)
Cited by 1
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830